- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06875700
Beliefs, Attitudes, and Interest in Genetic Testing in Sarcoma Patients (SPORE)
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients is not yet established. This study will assess beliefs about the heritability of leiomyosarcoma (LMS) and other cancers, and attitudes toward germline testing among LMS patients.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a descriptive study to explore attitudes toward genomics and interest in receiving personal genetic information among patients with leiomyosarcoma (LMS). The study aims to:
- Assess LMS patients' beliefs and attitudes about the heritability of LMS.
- Assess LMS patients' interest in genetic testing and their preferences for receiving information about genetic testing.
Prior studies of cancer patients have found strong interest in germline genetic testing to inform personal and familial cancer risk. However, germline genetic testing is not widely recommended for patients diagnosed with LMS, and little is known about patients' beliefs about the heritability of LMS or their interest in genetic testing. This study will use a survey to assess beliefs about the heritability of LMS, interest in genetic testing, and preferences for receiving information about genetic testing.
Participants will be identified by querying the Enterprise Data Warehouse (EDW) and the Huntsman Tumor Registry, recruiting in clinics at the Huntsman Cancer Institute, receiving referrals from providers outside the Huntsman Cancer Institute, and through LMS patient support and advocacy organizations.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Gregg Wood
- Número de teléfono: 801-646-4215
- Correo electrónico: gregg.wood@hci.utah.edu
Ubicaciones de estudio
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Reclutamiento
- Huntsman Cancer Institute at the University of Utah
-
Contacto:
- Wendy K Kohlmann, MS
- Número de teléfono: 801-587-5556
- Correo electrónico: wendy.kohlmann@hci.utah.edu
-
Investigador principal:
- Wendy K Kohlmann, MS
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population will be Patients with a confirmed or self reported diagnosis of LMS
Descripción
Inclusion
- Living
- Able to speak and read English or Spanish
- Mentally competent
- Age 18 or older
Exclusion
- <18 years
- Unable to read or write
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Patients with leiomyosarcoma
Electronic questionnaire assessing beliefs about the heritability of LMS and interest in genetic testing |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Beliefs about the heritability of Leiomyosarcoma
Periodo de tiempo: up to 1 day from study enrollment
|
This outcome will describe LMS patients' beliefs about the heritability of LMS as well as other cancers, diseases, and physical traits. A five point Likert scale is used to classify conditions from totally inherited to totally environmental. |
up to 1 day from study enrollment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Interest in germline genetic testing
Periodo de tiempo: up to 1 day from study enrollment
|
This outcome will report interest in genetic testing for cancer predisposition for themselves as well as for other people such as family members, children, and the general public. Likert scales will be used to assess general interest in genetics and genetic testing in general. Interest in genetic testing will also be assessed with questions about when in the lifespan testing should be offered and for which types of conditions. |
up to 1 day from study enrollment
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Preferences for receiving information about genetic testing.
Periodo de tiempo: up to 1 day from study enrollment
|
This outcome will report the count of participants who self reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported >5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically . |
up to 1 day from study enrollment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Wendy Kohlmann, MS, Huntsman Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 165523
- 1P50CA272170-01 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Deidentified IDP will be shared with the University of Michigan Rogel Cancer Center for data analysis.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .